Intermediate Risk News Today

Transcatheter aortic valve replacement (TAVR) was found to bring no increased risks and was associated with substantial decreased rates of death or stroke at one year in low-risk patients, compared with surgical aortic valve replacement (SAVR), according to findings presented at the American College of Cardiology's Annual Scientific Session.

REDWOOD CITY, Calif., Dec. 10, 2023 -- Jasper Therapeutics, Inc. , a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit to address mast cell...

First Patient Dosed in Phase 1 trial of Briquilimab in Lower-Risk Myelodysplastic SyndromeStrengthened the Board of Directors and Management Team with Multiple Appointments REDWOOD CITY, Calif., Aug....

Key opinion leaders in the field of renal cell carcinoma management discuss the advent of combination immunotherapy in patients with metastatic disease.

The panel closes their discussion with a look at the standards for genetic counseling for patients with non-clear cell RCC.

The panel discusses the best approaches to treating patients with non-clear cell RCC.

Mehmet Asim Bilen, MD, explains how he would treat a patient with renal cell carcinoma who had disease progression after adjuvant therapy.

The panel discusses recent clinical trial data in the adjuvant treatment of metastatic renal cell carcinoma.

The panel discusses the use of quality-of-life clinical trial data in metastatic renal cell carcinoma and how liver and brain metastases affect treatment decision-making.

Mehmet Asim Bilen, MD, details how he approaches IO/TKI therapy for patients with renal cell carcinoma with bone metastases.